Upstream Bio, Inc.
- UPB
- NASDAQ
- Biotechnology
- Clinical-Stage Biotech
- Respiratory/Inflammation Therapy
- Monoclonal Antibody (Verekitug)
$2.80
Today +1.45%Quote Oct 19, 2026, 08:00 PM UTC
−47.57%over the last month
Max drawdown −49.7%From 1-month high −49.0%3 months −59.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Upstream Bio
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
75
Market value
$153.4M
Quote Oct 19
Analyst target
$25.00
+792.9% from here
Floor
$2.09
25.2% below price
Resistance
$3.41
21.7% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about UPBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free